SCHEDULE 13G: Goldman Sachs Discloses 6.0% Passive Stake in Chimerix, Inc.
Beneficial Ownership Report
The Goldman Sachs Group, Inc. and its affiliate, Goldman Sachs & Co. LLC, have reported a 6.0% beneficial ownership stake in Chimerix, Inc. common stock through a Schedule 13G filing.
Summary
- The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC are the reporting persons in this Schedule 13G filing.
- They collectively beneficially own 5,667,503.95 shares of Chimerix, Inc. common stock.
- This ownership represents 6.0% of the total outstanding common stock of Chimerix, Inc.
- The shares are held with shared voting power and shared dispositive power.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Chimerix, Inc.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of a significant passive ownership stake by a major financial institution, which is generally viewed as neutral to slightly positive due to the implied institutional interest.
Positives
- A major financial institution like Goldman Sachs taking a significant passive stake (6.0%) can be viewed as a vote of confidence in Chimerix, Inc.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Chimerix, Inc.'s operations or financial performance. It solely reports a beneficial ownership stake by Goldman Sachs.
Industry Context
This filing is a routine disclosure of institutional ownership, common in the financial industry when an entity crosses a 5% beneficial ownership threshold in a publicly traded company. It indicates Goldman Sachs's investment in Chimerix, Inc., a company operating in the biotechnology or pharmaceutical sector, without implying any active management or control intent.
Stakeholder Impact
- Shareholders of Chimerix, Inc. may view the significant stake taken by Goldman Sachs as a positive signal of institutional confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-07-29 | Effective date of Power of Attorney for The Goldman Sachs Group, Inc. |
| 2024-10-01 | Effective date of Power of Attorney for Goldman Sachs & Co. LLC |
| 2025-03-31 | Date of event which requires filing of this statement |
| 2025-04-02 | Date of filing and signature for both reporting persons |
| 2025-07-29 | Expiration date of Power of Attorney for The Goldman Sachs Group, Inc. |
| 2025-10-01 | Expiration date of Power of Attorney for Goldman Sachs & Co. LLC |
Keywords
Chimerix, Goldman Sachs, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.